How shall we treat locally advanced triple negative breast cancer?

Triple negative breast cancer (TNBC) has been shown to respond to neoadjuvant chemotherapy (NACT). It has been established that achieving pathological complete response (pCR) for certain aggressive subtypes of breast cancer, including HER-2 (over-expressed) and TNBC, provides an important surrogate...

Descripción completa

Detalles Bibliográficos
Autores principales: Luz, Paulo, Dias, David, Fortuna, Ana, Bretes, Luis, Gosalbez, Beatriz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Opinion Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411516/
https://www.ncbi.nlm.nih.gov/pubmed/32802311
http://dx.doi.org/10.12688/f1000research.20509.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411516/
https://www.ncbi.nlm.nih.gov/pubmed/32802311
http://dx.doi.org/10.12688/f1000research.20509.2

Ejemplares similares